These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26112923)

  • 1. Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.
    Urbanska K; Stashwick C; Poussin M; Powell DJ
    Cancer Immunol Res; 2015 Oct; 3(10):1130-7. PubMed ID: 26112923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
    Perales-Puchalt A; Svoronos N; Rutkowski MR; Allegrezza MJ; Tesone AJ; Payne KK; Wickramasinghe J; Nguyen JM; O'Brien SW; Gumireddy K; Huang Q; Cadungog MG; Connolly DC; Tchou J; Curiel TJ; Conejo-Garcia JR
    Clin Cancer Res; 2017 Jan; 23(2):441-453. PubMed ID: 27435394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells.
    Wang C; Hu W; Shen L; Dou R; Zhao S; Shan D; Yu K; Huang R; Li H
    J Immunother; 2014 Sep; 37(7):351-9. PubMed ID: 25075564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.
    Perales-Puchalt A; Wojtak K; Duperret EK; Yang X; Slager AM; Yan J; Muthumani K; Montaner LJ; Weiner DB
    Mol Ther; 2019 Feb; 27(2):314-325. PubMed ID: 30554854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
    Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
    Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
    Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-specific T cells combine proliferation and antitumor activity.
    Kershaw MH; Westwood JA; Hwu P
    Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
    Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
    Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
    J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
    Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
    Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.